Canara HSBC Life Q2 FY27 call set for Oct 9, 2026

Key updates investors are tracking

Canara HSBC Life Insurance Company Ltd has scheduled a conference call with investors and analysts on October 9, 2026 to discuss its unaudited financial results for the quarter and half-year ended September 30, 2026. The call is set for 6:00 pm IST, with participants advised to dial in by 5:55 pm IST. The company has also informed stock exchanges that its board will meet on the same day to approve the unaudited results and the limited review report. Separately, the board is expected to consider a proposal to raise funds through the issuance of non-convertible debentures (NCDs). For life insurers, quarterly disclosures typically draw attention to premium trends and profit movement, so the October 9 schedule is a key near-term milestone for the stock.

Conference call details for October 9

The investor and analyst call is intended to cover the company’s unaudited performance for Q2 FY27 and H1 FY27. The management team is expected to discuss business performance during the second quarter of FY27, based on the company’s stated call agenda. The timing of 6:00 pm IST suggests the discussion may follow the board’s consideration of results. Investors usually look for commentary on premium growth, product mix and profitability, although the company’s detailed commentary will only be known after the results are announced. Market participants will also watch for clarity on any actions connected to the NCD fundraising proposal. No amount or timeline for the NCD plan was provided in the shared filing excerpts.

Board meeting agenda includes results and NCD proposal

Exchange communication indicates the board meeting on October 9, 2026 will cover three items: approval of unaudited financial results for the quarter and half-year ended September 30, 2026; approval of the limited review report; and consideration of fundraising via non-convertible debentures. Such combined agendas are common when companies align financing discussions with financial disclosures. Any NCD issuance would be subject to the board’s approval process as outlined in the meeting agenda. Investors typically monitor these proposals for their implications on liquidity, leverage and funding costs. At this stage, the only confirmed information is that the proposal will be considered.

Trading window closure around the results

The company also informed the National Stock Exchange of India and BSE that it would close its trading window for securities from October 1, 2026. The trading window is expected to reopen 48 hours after the announcement of the unaudited financial results for the quarter ending September 30, 2026. This is consistent with standard compliance practices around unpublished price-sensitive information. The reopening timeline is linked to the results announcement rather than to the conference call itself. Investors and employees subject to the code typically avoid trading during the closure period.

First-year premium slips in September

Alongside the results-related updates, the company reported a first-year premium of INR 3.72 billion in September, a 1.6% decline year over year. Normalised to a common base unit, that equals about Rs 372 crore. First-year premium is closely watched because it reflects new business intake and the pace of fresh policy sales. A year-on-year decline, even modest, can be a signal investors track in the context of broader premium momentum and product strategy. More context on the drivers may emerge when management discusses the half-year performance. The September number, by itself, does not provide a full view of quarterly premium trends.

What the latest available quarterly numbers show

The most recent quarter referenced in the provided data is Q1 FY27 (quarter ended June 30, 2026). For that quarter, the company reported revenue of about Rs 4,351 crore and a net profit of Rs 28.00 crore. The reported EPS figure referenced in the data is 1.38, while another quarterly table shows EPS of Rs 0.30 for the June 2026 quarter. The dataset also states Q1 FY27 net profit rose 20.15% year on year to Rs 28.14 crore, supported by growth in premium income, investment income and the protection business. Net premium income for Q1 is described as rising 23.83% year on year. These figures set the backdrop for what investors will compare against when Q2 and H1 FY27 numbers are released.

Earlier uncertainty on Q2 date, later filings set Oct 9

One set of notes in the provided information said that, as of September 17, 2026, the Q2 FY27 results date was not confirmed and that the company had not filed a board meeting intimation by that date. The same notes referenced listing rules that require September quarter results within 45 days, implying an outer deadline of November 14, 2026. Later items dated October 6 state the board meeting is scheduled for October 9 to approve Q2 and H1 FY27 results and to consider NCD fundraising, alongside the investor call intimation. Taken together, the timeline suggests the company subsequently formalised the October 9 date through exchange communication.

Financial snapshot and comparison points

The September 2025 quarter (Q2 FY26) is referenced as a comparison base, with revenue of Rs 2,348 crore and net profit of Rs 41 crore. The same dataset lists Q1 FY26 revenue of Rs 3,632 crore and Q1 FY27 revenue of Rs 4,351 crore, along with Q1 FY26 net profit of Rs 23 crore and Q1 FY27 net profit of Rs 28 crore. These numbers highlight that profits can vary significantly quarter to quarter, even when revenue expands, which is why management commentary on margins, mix and investment-related items matters for interpretation. Investors will likely use the Q2 FY26 base and Q1 FY27 run-rate as the most immediate reference points.

Market impact: what could move after disclosures

The confirmed near-term catalyst is the release of unaudited Q2 and H1 FY27 results, followed by the 6:00 pm call on October 9. Investors will parse the reported numbers against prior quarters, including Q1 FY27 revenue of about Rs 4,351 crore and net profit of about Rs 28 crore. The first-year premium data point for September, at about Rs 372 crore and down 1.6% year on year, will add to the discussion around new business momentum. Any board-approved decision on NCD fundraising could also become material for market participants, depending on the eventual size and terms, which are not provided in the current information. Separately, the trading window reopening 48 hours after results provides a clear compliance marker tied to the announcement.

Why this event matters for the insurer

The October 9 schedule combines three developments that markets typically track closely: board approval of results, a management call, and a funding proposal discussion. For a life insurer, quarterly outcomes can reflect shifts in premium income, investment income and product mix, and the dataset specifically links Q1 FY27 profit growth to these factors. The board’s consideration of NCD issuance introduces an additional angle because it signals a review of funding options. With Q2 FY26 profit cited at Rs 41 crore versus Q1 FY27 profit of Rs 28 crore, investors will be attentive to how profitability moved through the first half. The company’s disclosures on October 9 will provide the verified basis for that assessment.

Conclusion

Canara HSBC Life has set October 9, 2026 as a key date, with the board slated to approve unaudited Q2 and H1 FY27 results and consider NCD fundraising, followed by a 6:00 pm investor call. The next confirmed step is the results announcement and related exchange filings on that day, after which the trading window is set to reopen 48 hours later.